Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease
- 1Gubra A/S Hørsholm Denmark
- 2Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riss Germany
Abstract
Aims: Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function in chronic kidney disease (CKD), including diabetic kidney disease (DKD). This study aimed to characterize the effects of survodutide in a translational mouse model of advanced DKD, induced by adeno‐associated virus‐mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) diabetic db/db mice.
Materials and Methods: Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post‐UNx, db/db UNx‐ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks. Endpoints included blood/urine biochemistry, histological markers of glomerulosclerosis, tubular injury and inflammation, as well as quantitative 3D whole‐pancreas and whole‐kidney imaging.
Results: Compared to vehicle controls, survodutide reduced body weight, hyperglycemia, and HbA1c levels concurrent with improved hyperinsulinemia and β‐cell islet volume distribution. Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation. 3D whole‐kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity. Survodutide reduced liver weight and plasma amino acid levels, including alanine, confirming hepatic glucagon receptor activation.
Conclusions: Survodutide markedly improved metabolic and renal outcomes in the db/db UNx‐ReninAAV mouse model of advanced DKD, supporting further investigation into therapeutic options of survodutide in chronic kidney diseases.
Related
- Anti-Hyperglycaemic, Hepatoprotective, and Nephroprotective Effects of Wrightia tinctoria Seeds and Enterococcus ratti in Alloxan-Induced Diabetic Mice
- Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty
- GLP-1 Receptor Agonist Initiation and Anti-VEGF Treatment Frequency in Diabetic Macular Edema: an IRIS(R) Registry Cohort Study
- Survodutide Once Weekly for the Treatment of Adults with Obesity
- Development and Validation of a Prediction Model for Pulmonary Arterial Hypertension in Diabetic Patients: A Retrospective Study of 57,375 Patients.
BibTeX
@article{hamilton2026nephroprotective,
title = {{Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease}},
author = {Alexander Hamilton and Louise Thisted and Maria Ougaard and Max Hahn and Kasper Andersen and Johanna Perens and Robert Augustin and Besnik Bajrami and Wolfgang Rist and Michael Christensen and Henrik H. Hansen and Thomas Klein},
journal = {Diabetes, Obesity \& Metabolism},
year = {2026},
month = oct,
doi = {10.1111/dom.71387},
url = {https://doi.org/10.1111/dom.71387},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease
AU - Alexander Hamilton
AU - Louise Thisted
AU - Maria Ougaard
AU - Max Hahn
AU - Kasper Andersen
AU - Johanna Perens
AU - Robert Augustin
AU - Besnik Bajrami
AU - Wolfgang Rist
AU - Michael Christensen
AU - Henrik H. Hansen
AU - Thomas Klein
PY - 2026
DA - 2026/10/01
JO - Diabetes, Obesity & Metabolism
DO - 10.1111/dom.71387
UR - https://doi.org/10.1111/dom.71387
AB - Aims: Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function in chronic kidney disease (CKD), including diabetic kidney disease (DKD). This study aimed to characterize the effects of survodutide in a translational mouse model of advanced DKD, induced by adeno‐associated virus‐mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) diabetic db/db mice. Materials and Methods: Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post‐UNx, db/db UNx‐ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks. Endpoints included blood/urine biochemistry, histological markers of glomerulosclerosis, tubular injury and inflammation, as well as quantitative 3D whole‐pancreas and whole‐kidney imaging. Results: Compared to vehicle controls, survodutide reduced body weight, hyperglycemia, and HbA1c levels concurrent with improved hyperinsulinemia and β‐cell islet volume distribution. Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation. 3D whole‐kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity. Survodutide reduced liver weight and plasma amino acid levels, including alanine, confirming hepatic glucagon receptor activation. Conclusions: Survodutide markedly improved metabolic and renal outcomes in the db/db UNx‐ReninAAV mouse model of advanced DKD, supporting further investigation into therapeutic options of survodutide in chronic kidney diseases.
SN - 1462-8902
SN - 1463-1326
ER -